Patents by Inventor Timothy P. Kogan
Timothy P. Kogan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6713604Abstract: The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of &agr;4&bgr;1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses &agr;4&bgr;1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.Type: GrantFiled: May 8, 1996Date of Patent: March 30, 2004Assignee: Texas Biotechnology CorporationInventors: Timothy P. Kogan, Kaijun Ren, Peter Vanderslice, Pamela J. Beck
-
Patent number: 6582928Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 2, 2000Date of Patent: June 24, 2003Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 6262084Abstract: A method for the inhibition of the binding of &agr;4&bgr;1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions thereof; and the use of the compounds either as above, or in formulations for the control or prevention of diseases states in which &agr;4&bgr;1 is involved.Type: GrantFiled: October 14, 1999Date of Patent: July 17, 2001Assignee: Texas Biotechnology CorporationInventors: Ronald J. Biediger, Vanessa O. Grabbe, George W. Holland, Jamal Kassir, Karin M. Keller, Timothy P. Kogan, Shuqun Lin, Robert V. Market, Bore G. Raju, Ian L. Scott, Chengde Wu
-
Patent number: 6194448Abstract: A method for the inhibition of the binding of &agr;4&bgr;1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of diseases states in which &agr;4&bgr;1 is involved.Type: GrantFiled: October 14, 1999Date of Patent: February 27, 2001Assignee: Texas Biotechnology CorporationInventors: Ronald J. Biediger, Vanessa O. Grabbe, George W. Holland, Jamal M. Kassir, Timothy P. Kogan, Shuqun Lin, Robert V. Market, Bore G. Raju, Ian L. Scott, Chengde Wu
-
Patent number: 6124435Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: December 22, 1998Date of Patent: September 26, 2000Assignee: Genetech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 6096773Abstract: A method for the inhibition of the binding of .alpha..sub.4 .beta..sub.1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of diseases states in which .alpha..sub.4 .beta..sub.1 is involved.Type: GrantFiled: April 15, 1999Date of Patent: August 1, 2000Assignee: Texas Biotechnology Corporation, Inc.Inventors: Ian L. Scott, Bore G. Raju, Ronald J. Biediger, Vanessa O. Grabbe, Jamal Kassir, Karin M. Keller, Timothy P. Kogan, deceased, Shuqun Lin, Robert V. Market
-
Patent number: 6087330Abstract: The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of .alpha..sub.4 .beta..sub.1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses .alpha..sub.4 .beta..sub.1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.Type: GrantFiled: April 13, 1998Date of Patent: July 11, 2000Assignee: Texas Biotechnology CorporationInventors: Timothy P. Kogan, Kaijun Ren, Peter Vanderslice, Pamela J. Beck
-
Patent number: 5929211Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: September 4, 1997Date of Patent: July 27, 1999Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5919768Abstract: The present invention provides compounds having structure (II), and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof.Type: GrantFiled: February 11, 1998Date of Patent: July 6, 1999Assignee: Texas Biotechnology CorporationInventors: Timothy P. Kogan, Brian Dupre, Ian L. Scott, Huong Bui, Kathy L. Wheeler, Karin M. Keller, Jamal M. Kassir
-
Patent number: 5889155Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 31, 1995Date of Patent: March 30, 1999Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5783705Abstract: A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.Type: GrantFiled: April 28, 1997Date of Patent: July 21, 1998Assignee: Texas Biotechnology CorporationInventors: Natalie Blok, Chengde Wu, Karin Keller, Timothy P. Kogan
-
Patent number: 5776907Abstract: The present invention provides conjugates of mitomycin C or derivatives thereof and oligonucleotides. A conjugate of the present invention corresponds to formula I, below: ##STR1## where R is H, CH.sub.3, or C(O)SCH.sub.3, R' is O or NH, m is an integer from 1 to 10 and Ogn is an oligonucleotide. Pharmaceutical compositions and methods of using such conjugates to inhibit gene product expression are also provided.Type: GrantFiled: May 20, 1996Date of Patent: July 7, 1998Assignee: Texas Biotechnology CorporationInventors: Harold L. Kohn, Nam Huh, Timothy P. Kogan, Ajay A. Rege
-
Patent number: 5712387Abstract: A process of preparing mannosylated alcohols or phenols in high chemical yield and purity using tetra-O-pivaloylmannosylfluoride and a Lewis acid catalyst.Type: GrantFiled: May 20, 1996Date of Patent: January 27, 1998Assignee: Texas Biotechnology CorporationInventors: Ian L. Scott, Timothy P. Kogan, Harold Meckler
-
Patent number: 5622937Abstract: This invention relates to compounds that inhibit the binding of E-selectin or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface having the general structure: ##STR1## This invention also relates to methods of inhibiting the binding of E-selectin or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E-selectin to sialyl-Lewis.sup.x and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occurs following heart attacks, strokes and organ transplants and to the treatment of cancer.Type: GrantFiled: May 1, 1996Date of Patent: April 22, 1997Assignee: Texas Biotechnology CorporationInventors: Timothy P. Kogan, Brian Dupre, Huong Dao, Pamela J. Beck
-
Patent number: 5605791Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 31, 1995Date of Patent: February 25, 1997Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5510332Abstract: The present invention is directed to an isolated and purified peptide comprising the LDV domain of the CSI peptide sequence or single amino acid substitutent analog thereof. A preferred peptide has the amino acid residue sequences shown in SEQ ID NOs:8-14, 17-23, 25, 28, and 51. The present invention is further directed to a process of inhibiting the binding of .alpha..sub.4 .beta..sub.1 integrin to a protein such as VCAM-1 or fibronectin comprising exposing a cell that expresses .alpha..sub.4 .beta..sub.1 integrin to the protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition comprising a peptide of SEQ ID NO:8-102.Type: GrantFiled: July 7, 1994Date of Patent: April 23, 1996Assignee: Texas Biotechnology CorporationInventors: Timothy P. Kogan, Kaijun Ren, Peter Vanderslice, Pamela J. Beck
-
Patent number: 5444050Abstract: This invention relates to compounds that inhibit the binding of E-selectin and/or P-selectin to sialyl-Lewis.sup.x or sialyl-Lewis.sup.a presented on a cell surface having the general structure ##STR1## wherein X is selected from the group consisting of --(CH.sub.2).sub.n CO.sub.2 H, --O(CH.sub.2).sub.m CO.sub.2 H, --(CH.sub.2).sub.n O(CH.sub.2).sub.m CO.sub.2 H, --CONH(CH.sub.2).sub.m CO.sub.2 H, --CH(OZ)(CO.sub.2 H), --CH(Z)(CO.sub.2 H), --(CH.sub.2).sub.n SO.sub.3 H, --(CH.sub.2).sub.n PO.sub.3 D.sub.1 D.sub.2, --NH(CH.sub.2).sub.m CO.sub.2 H, --CONH(CHR.sub.6)CO.sub.2 H, (1-H-tetrazolyl-5-alkyl-), and --OH;R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, alkyl, halogen, --OZ, --NO.sub.2, --NH.sub.2 and --NHZ;R.sub.3 is selected from the group consisting of hydrogen, halogen, alkyl, --OZ and --NHZ;R.sub.4 is selected from the group consisting of hydrogen, halogen, alkyl, hydroxyl, hydroxyl-O-sulfate and --OZ;R.sub.Type: GrantFiled: April 29, 1994Date of Patent: August 22, 1995Assignee: Texas Biotechnology CorporationInventors: Timothy P. Kogan, Brian Dupre, Ian L. Scott, Karin Keller, Huong Dao, Pamela J. Beck
-
Patent number: 5384331Abstract: 5,6-Dehydronorketamine and derivatives retaining the .alpha.,.beta.-unsaturated carbonyl are disclosed. These end other Michael or Michael-type acceptors and adducts are shown to influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.Type: GrantFiled: May 28, 1993Date of Patent: January 24, 1995Assignee: Genentech, Inc.Inventors: Timothy P. Kogan, Todd C. Somers
-
Patent number: 5329028Abstract: The invention is from the field of heterobifunctional cross-linking reagents. More particularly, the invention concerns cross-linking reagents which combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, thereby allowing coupling of aldehydes to free thiols.Type: GrantFiled: August 5, 1992Date of Patent: July 12, 1994Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5250732Abstract: 5,6-Dehydronorketamine and derivatives retaining the .alpha.,.beta.-unsaturated carbonyl are disclosed. These and other Michael or Michael-type acceptors and adducts are shown to influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.Type: GrantFiled: July 18, 1991Date of Patent: October 5, 1993Assignee: Genentech, Inc.Inventors: Timothy P. Kogan, Todd C. Somers